603456.SS Overview

Company Profile

Zhejiang Jiuzhou Pharmaceutical Co., Ltd operates as contract development and manufacturing organization (CDMO) company in China and internationally. The company offers small molecules, drug products, and peptide CDMO services. It also involved in business related to supporting the development of new drugs and pharmaceuticals. It serves global pharmaceutical companies, biotechnology companies, and scientific research institutions. Zhejiang Jiuzhou Pharmaceutical Co., Ltd was founded in 1973 and is headquartered in Taizhou, China.

Related stocks

605507.SS

605507.SS • China

GUOBANG PHARMA LTD

17.31 CNY

2.03B USD 1Y +7.4%

600867.SS

600867.SS • China

TONGHUA DONGBAO MEDICINES CO LT

7.88 CNY

2.31B USD 1Y -7%

1513.HK

1513.HK • China

22.16 HKD

2.51B USD 1Y -35.7%

002399.SZ

002399.SZ • China

9.89 CNY

2.17B USD 1Y -16.7%

002755.SZ

002755.SZ • China

13.34 CNY

1.85B USD 1Y -32.7%

600267.SS

600267.SS • China

ZHEJIANG HISUN PHARMACEUTICAL C

11.94 CNY

2.11B USD 1Y +13.5%

600380.SS

600380.SS • China

JOINCARE PHARMACEUTICAL GROUP I

10.13 CNY

2.77B USD 1Y -19.3%

600420.SS

600420.SS • China

SHANGHAI SHYNDEC PHARMACEUTICAL

8.51 CNY

1.71B USD 1Y -20.2%

Key Metrics & Overview

Detailed metrics & financial data of the company

Company Profile

5 Metrics

Country

Region

Sector

Industry

Drug Manufacturers - Specialty & Generic

Website

https://www.jiuzhoupharma.com

🛡️ Risk & Structural Analysis

Multi-Factor Risk Model & Market Data

7/7 Very High

5Y Volatility

43.1% p.a.

Max Drawdown (5Y)

-80.5%

Sharpe Ratio (5Y)

-0.55

Beta Factor

0.13

Size Class

Large Cap

Notes & Warnings

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).

Exemplary balance sheet strength: Very solid ratio of equity to debt.

🔴 Low analyst coverage – higher uncertainty in growth estimates & projections

Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (43.1% p.a.).

Historical Stress Test: Maximum peak-to-trough drawdown of -80.5% in the extended horizon.